Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Isolated lopinavir resistance after virological rebound of a ritonavir/lopinavir-based regimen.

AIDS (London, England) - 24 Sept 2004

Friend John, Parkin Neil, Liegler Teri, Martin Jeffrey N, Deeks Steven G

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-HIV Agents
Share to Drug Resistance, Multiple, Viral
Share to HIV Infections
Share to Lopinavir

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Pyrimidinones

Share to Ritonavir

Share to RNA, Viral

Source

Identifiers

PMID: 15353986
DOI: 10.1097/00002030-200409240-00016

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Isolated lopinavir resistance after virological rebound of a ritonavir/lopinavir-based regimen.PMID 15353986Read ↗

Genotypic resistance at viral rebound among patients who received lopinavir/ritonavir-based or efavirenz-based first antiretroviral therapy in South Africa.Semantic proximity Read ↗

Drug resistance is rarely the cause or consequence of long-term persistent low-level viraemia in HIV-1-infected patients on ART.Semantic proximity Read ↗

Differing reverse transcriptase mutation patterns in individuals experiencing viral rebound on first-line regimens with stavudine/didanosine and stavudine/lamivudine.Semantic proximity Read ↗

Lopinavir/ritonavir monotherapy after virologic failure of first-line antiretroviral therapy in resource-limited settings.Semantic proximity Read ↗

Virological success of lopinavir/ritonavir salvage regimen is affected by an increasing number of lopinavir/ritonavir-related mutations.Semantic proximity Read ↗

Salvage treatment with lopinavir/ritonavir (Kaletra) in HIV-infected patients failing all current antiretroviral drug families.Semantic proximity Read ↗

The natural history and clinical significance of intermittent viraemia in patients with initial viral suppression to < 400 copies/ml.Semantic proximity Read ↗

Characterization of associations and development of atazanavir resistance after unplanned treatment interruptions.Semantic proximity Read ↗

Phenotypic characterization of virological failure following lopinavir/ritonavir monotherapy using full-length Gag-protease genes.Semantic proximity Read ↗

Persistence of HIV-1 drug resistance mutations and emergence during antiretroviral treatment interruption: considerations from a clinical case.Semantic proximity Read ↗

Viral Load Rebound in Placebo and Nirmatrelvir-Ritonavir Treated COVID-19 Patients is not Associated with Recurrence of Severe Disease or MutationsSemantic proximity Read ↗

Detection of drug resistance mutations as a predictor of subsequent virological failure in patients with HIV-1 viral rebounds of less than 1,000 RNA copies/ml.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.